Drugs / PL-18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05340790 | Aug 2022 → Dec 2023 | bacterial vaginosis, fungal infectious disease, vulvovaginitis | Protelight Pharmaceuticals Australia PTY LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05340790 ↗ |
| Modality | Peptide | “Antimicrobial Peptide PL-18 Vaginal Suppositories” NCT05340790 ↗ |
| Route | Topical | “topical vaginal suppository” NCT05340790 ↗ |